QIAGEN OmicSoft and Biomedical Knowledge Base

Public single cell RNA-seq data investigation using Omicsoft and Ingenuity Pathway Analysis

558 views
October 12, 2022
Slides from this training:
https://qiagen.showpad.com/share/qm9IZA718x6x5h6pfsiTa

Single cell lands tutorials: https://omicsoftdocs.github.io/ArraySuiteDoc/tutorials/SingleCellLand/Gene_Views/

Single cell RNA-sequencing (scRNA-seq) has been widely used to investigate tissue heterogeneity, identify novel cell types, study pathogenic mechanisms, development of targeted therapy (including immunotherapy) and more. Accordingly tremendous amount of scRNA-seq data has been deposited to public domains like GEO.

In this training, attendees will learn how to

· Locate public single cell studies of their interest using Omicsoft Single Cell Lands

· Study different cell types by dimension reduction plots (example t-SNE, UMAP)

· Investigate expression of genes of interest across different cell types (Violin plots, overlay expression on cluster)

· Identify key pathways and regulators from scRNA-seq data using Ingenuity Pathway Analysis

Related videos

QIAGEN OmicSoft and Biomedical Knowledge Base

Public single-cell RNA-seq data investigation using QIAGEN OmicSoft and Ingenuity Pathway Analysis

51 views February 29, 2024

Single-cell RNA-sequencing (scRNA-seq) is widely used to investigate tissue...

QIAGEN OmicSoft and Biomedical Knowledge Base

Investigating public scRNA data using OmicSoft and QIAGEN IPA

192 views November 04, 2022

Single cell RNA-sequencing (scRNA-seq) has been widely used to investigate...

QIAGEN OmicSoft and Biomedical Knowledge Base

Checkpoint inhibitors investigation in context of biomarkers, drug targets and pathways using...

273 views September 15, 2022

This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to...

QIAGEN OmicSoft and Biomedical Knowledge Base

Exploring drug response in low-grade glioma

284 views August 31, 2022

See how Dr, Nilson from QIAGEN Digital Insights navigates an interesting...